Download Citation
Article Source:
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
Anywaine Z,
Barry H,
Anzala O,
Mutua G,
Sirima SB,
et al.
(2022)
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
PLOS Medicine 19(1): e1003865.
https://doi.org/10.1371/journal.pmed.1003865